In a time of increasing competition for clinical services resources, it is imperative that health professionals actively participate in the commissioning process in order to ensure that established clinical standards are not compromised. Introduction of the NHS reforms in the UK in the early 1990s highlighted the difficulties in contracting for a specialised service such as clinical genetics, especially in the absence of a consensus regarding the contract currency. An average block contract price for each new family referred was introduced in Wales in 1992, and data from the subsequent five years show that this charging system is economically feasible and has the advantages of (1) recognising the contribution to care of non-medical personnel on the genetics team, (2) covering follow up including the counselling of relatives, (3) protecting the service from loss of income owing to non-attendance, and (4) providing a basis for negotiation when new services are being proposed to purchasers. Activity data show that while the majority of conditions incur below average cost, the mean cost is influenced by a small number of autosomal dominant and X linked disorders. The cost risk to the provider for seeing families over an extended period is miinimal, as the data establish that family files experience an exponential decrease in activation probability over the early years, but this becomes constant later on.
In a time of increasing competition for clinical services resources, it is imperative that health professionals actively participate in the commissioning process in order to ensure that established clinical standards are not compromised. Introduction of the NHS reforms in the UK in the early 1990s highlighted the difficulties in contracting for a specialised service such as clinical genetics, especially in the absence of a consensus regarding the contract currency. An average block contract price for each new family referred was introduced in Wales in 1992, and data from the subsequent five years show that this charging system is economically feasible and has the advantages of (1) recognising the contribution to care of non-medical personnel on the genetics team, (2) covering follow up including the counselling of relatives, (3) protecting the service from loss of income owing to non-attendance, and (4) providing a basis for negotiation when new services are being proposed to purchasers. Activity data show that while the majority of conditions incur below average cost, the mean cost is influenced by a small number of autosomal dominant and X linked disorders. The cost risk to the provider for seeing families over an extended period is miinimal, as the data establish that family files experience an exponential decrease in activation probability over the early years, but this becomes constant later on. The robustness of the system is dependent on accurate baseline data on referral patterns to the Clinical services face increasing competition for resources in virtually all countries. The "purchaser", be it government, health insurer, or private client, justifiably demands accurate accountability for any financial transfer. In the United Kingdom, changes in the NHS organisation in the early 1990s introduced a "purchaser/provider" split, which included general practitioner purchasing via fund holding, and these changes have highlighted the potential difficulties in contracting for a specialised regional service such as clinical genetics. Unlike most other hospital based specialities, clinical genetic consultations or "patient episodes" usually deal with families (probands, consultands, and extended relatives) as opposed to individual people. Furthermore, the length of face to face contact hardly ever reflects the time and effort taken to address the families' concerns,' and the contribution to care by specialist nurses and genetic associates is not normally recognised as a chargeable outpatient service. Therefore contracting for clinical genetics poses particular problems, especially as there is no general consensus regarding the contract currency, and levels of manpower and the patterns of service delivery vary substantially between centres.2 In the UK, this situation has forced each of the regional genetic services to develop and agree with the purchasers its own method of commissioning and contracting. In this paper, we present the contracting system introduced in Wales in 1992. Data from the subsequent five years show that the Welsh contracting system is both economically viable and cost effective to administer.
Contract currency
The clinical genetic service in Wales (population 2.9 million) was established in Cardiff, the regional centre, in 1970, with continuing development of outreach services and locally based nurse specialists (co-workers) from the early 1980s (fig 1) . All standard counselling A computerised work activity profile was devised for completion by all health care professionals involved in the delivery of care (table 3) . Each activity code (table 2A, B) was accurately priced (different cost unit for physicians and co-workers) so that the total cost of activity to all families during the financial year was equal to the actual cost of the service. In addition to measuring activity, this computer program can be used to record other data (for example, the purchasing district, source of referral, waiting time for new referrals, diagnostic category), which allow different types of clinical activity to be related to each family referred, and comparison of demand associated with specific genetic disorders, such as Huntington's disease, muscular dystrophy, cystic fibrosis, etc (fig 2) .
Risks to purchaser With a block contract of the above nature, one of the main risks to the purchasers is payment for services which are not actually delivered. Therefore, confidence is required that the average cost per family referred is accurately represented by the contract price and that the activity generated is appropriate for a given family. Fig 2 shows that, while the majority of conditions incur below average price, the mean cost is influenced by the significant demand on resources of a small number of key genetic disorders (Huntington's disease, muscular dystrophy, and other similar autosomal dominant and X linked disorders). These conditions occasionally present with an extensive family history and a large number of at risk relatives. Although purchasers could decide to contract by disease category, this would be a disadvantage to both purchaser and provider: administrative costs could increase and, since referrals of cost intensive families are difficult to predict, uncertainties in budget planning and setting would result, especially when the poj covered by an individual purchaser is r small.
Risks to provider
The main risk to the provider is the res; ity for follow up which may involve extended family members over long pe time, sometimes even a generation. I are not discharged, they become "ir Therefore, the service provider has to ( carefully the probability of a file beini vated, and the contract price has to t account the proportion of follow ups in financial year. Various mathematical i ships can be presumed to hold between of a file and the probability of the file bt active in a given year. Knowledge relationship would allow both purchaE Table 5 Work activity (%/o of total) by disease (physicians and co-workers combi providers to make reliable predictions about 1' the work load expected from reactivated and newly opened files. Fig 3 shows the ratio between the active files in any one year and the accumulated number of files generated by a clinical genetic service over time. Data from three outreach clinics established in 1987/1988 are compared to data from the centre established in 1971/1972, and two mathematical models have been explored in more detail for these data (see Appendix). Model A assumes a constant annual activation probability, independent of age, while model B assumes an exponential decrease in activation probability with time. Over short periods of time, model B is by far more likely to be correct, but model A Y(, 1 0~a ppears to perform equally well over longer time periods (table 4) . Therefore, it may be that a combination of both models would be most meaningful, with activation probability decreasing exponentially up to a certain age of a file and staying constant thereafter.
With a referral rate of 350-400 new families/ million/year, as observed over the past five to six years, and an overall medical consultation follow up rate of approximately 50%, average costing per new family referred can sustain follow up in a kindred with multiple affected relatives. Furthermore, despite a highly significant variability in the activity profiles, as shown for Huntington's disease, cystic fibrosis, neural tube defects, and the muscular dystrophies ( fig   2) , average costing for a new family referred is -sensible since the relative distribution of work activity per year by disease has been fairly con-" clinical services are being considered. The robustness of the system is dependent on accurate baseline data on referral patterns to the service, staffing requirements, and costs.
This method of costing clinical components of genetic services was implemented in Wales in 1992, and experience over the past five years suggests that it is satisfactory to both purchasers and providers. The model shows that it is equal to the task of transforming a complex process into one that is relatively simple and one in which the purchasers can have confidence. The key determinants to the success of the model depend on outcome data and these now will have to be addressed. Challenges to the contracting method will emerge over the next few years when new services, such as those for breast cancer and other complex disorders, will be proposed to purchasers. However, in Wales there is now a firm basis established for future negotiation.
